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Ampicillin-ceftriaxone combination therapy has become a predominant treatment for serious Enterococcus faecalis infections,
such as endocarditis. Unfortunately, ceftriaxone use is associated with future vancomycin-resistant enterococcus colonization.
We evaluated E. faecalis in an in vitro pharmacodynamic model against simulated human concentration-time profiles of ampi-
cillin plus ceftaroline, cefepime, ceftriaxone, or gentamicin. Ampicillin-cefepime and ampicillin-ceftaroline demonstrated activi-
ties similar to those of ampicillin-ceftriaxone against E. faecalis.
Enterococcus faecalis is one of themost common causes of infec-tive endocarditis in hospitalized and/or immunocompro-
mised patients. The combination regimen of ampicillin plus
ceftriaxone has averted high-level aminoglycoside resistance
(HLAR) and improved the safety profile in E. faecalis endocarditis
treatment over the traditional regimen of ampicillin plus genta-
micin (1–4). Accordingly, ampicillin and ceftriaxone were re-
cently added as an option to treat both HLAR and non-HLAR E.
faecalis endocarditis, according to national guidelines (5). While
this regimen has increased safety for patients with serious E. faeca-
lis infections, it may create long-term collateral damage, as ceftri-
axone carries an increased risk of vancomycin-resistant Enterococ-
cus (VRE) gastrointestinal colonization (6, 7). This increase in
VRE colonization is likely due to ceftriaxone’s high biliary excre-
tion and is associated with increased risk for VRE bacteremia (6–
9). Cefepime and ceftaroline are cephalosporins with different
spectra of activity, distinct structures, and less biliary excretion;
therefore, they should carry less risk of VRE colonization (6, 10).
We therefore evaluated the activities of these dual -lactam com-
binations that have less potential for VRE colonization in a high-
inoculum in vitro pharmacodynamic (IVPD) infection model (6,
10, 11).
(A portion of the results were presented as a poster at the 54th
Interscience Conference on Antimicrobial Agents and Chemo-
therapy [ICAAC], 8 September 2014, Washington, DC.)
We evaluated two previously described strains of E. faecalis:
one ampicillin-susceptible and gentamicin-susceptible strain
(OG1X), and a -lactamase-producing although still ampicillin-
susceptible and HLAR gentamicin-resistant strain (HH22) (12,
13). Mueller-Hinton broth (MHB; Becton Dickinson, Sparks,
MD,USA), adjusted to 25mg/liter calciumand 12.5mg/litermag-
nesium,was used for in vitro pharmacodynamicmodels (14). Col-
ony counts were determined using tryptic soy agar (TSA; Difco,
Becton Dickinson). Ampicillin (App Pharmaceuticals, Schaum-
berg, IL), ceftriaxone (Hospira, Lake Forest, IL), cefepime (Sagent
Pharmaceuticals, Schaumberg, IL), ceftaroline research powder
(Forest Laboratories, New York, NY), and gentamicin (Sigma-
Aldrich, St. Louis, MO) were evaluated.
A previously described IVPD model was used to evaluate sev-
eral antibiotic regimens against enterococci at a high inoculum
(108 CFU/ml) over 24 h (15, 16). A 250-ml working-volume
glassmodel with inflow and outflowports controlled by peristaltic
pumps was used to achieve desired antibiotic concentrations and
half-lives. The regimens simulated free serum concentrations of
human doses, including 2 g of ampicillin every 4 h (maximum
concentration in serum [Cmax], 150g/ml; protein binding, 20%;
half-life, 1 h), 2 g of ceftriaxone every 12 h (Cmax, 257 g/ml;
protein binding, 90%; half-life, 6 h), 2 g of cefepime every 12 h
(Cmax, 163.9 g/ml; protein binding, 20%; half-life, 2 h), 600 mg
of ceftaroline every 12 h (Cmax, 21.3g/ml; protein binding, 20%;
half-life, 2.66 h), and 6 mg/kg of body weight of gentamicin every
24 h (Cmax, 24g/ml; protein binding, 0%; half-life, 2 h) (17–22).
For combination regimens, the rate was set for the drug with the
shorter half-life; the drug with the longer half-life was supple-
mented. The following regimens were tested: ampicillin alone,
ceftriaxone alone, cefepime alone, ampicillin plus ceftriaxone,
ampicillin plus cefepime, ampicillin plus ceftaroline, ampicillin
plus gentamicin, and no antibiotic (growth control).
All model experiments were performed at least in duplicate to
ensure reproducibility. Samples were removed from each model
at 0, 4, 8, and 24 h. Once removed, samples were serially diluted,
plated onTSA, and incubated at 37°C for 24 h before colony count
enumeration. The limit of detection for this method is 2.0 log10
CFU/ml. Antimicrobial carryover was minimized by serial dilu-
tion (1:10 to 1:10,000) of plated samples in conjunction with vac-
uum filtration, if needed, as previously described (23).
TheMICs of the antimicrobial agentswere determined by Etest
methodology (Table 1). All samples were incubated at 37°C in
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ambient air for 24 h. Etests were also used to assess changes inMIC
at 24 h to detect resistance.
Changes in log10 CFU/ml were plotted to demonstrate reduc-
tion by each regimen over 24 h. Bactericidal activity (99.9% kill)
was defined as a 3-log10 CFU/ml reduction and bacteriostatic
activity as a 3-log10 CFU/ml change in colony count from the
initial inoculum.
Changes in bacterial growth (log10 CFU/ml) at 24 h were
compared by analysis of variance with Tukey’s post hoc test. A P
value of0.05 was considered significant. All statistical analy-
ses were performed using SPSS statistical software (SPSS 22,
Inc., Chicago, IL).
Against both isolates, ampicillin-cefepime and ampicillin-cef-
taroline demonstrated greater activity than that of ampicillin-gen-
tamicin at 24 h (mean difference in log10 CFU/ml, 2.29 to 3.69;
P 0.02 for all) (Fig. 1). The activity of ampicillin-ceftriaxonewas
not significantly different than that of ampicillin-ceftaroline or
ampicillin-cefepime. Ampicillin-gentamicin was no more active
than ampicillin alone against either strain, likely due to high-level
aminoglycoside resistance of HH22 and once-daily gentamicin
dosing.
Against the gentamicin-susceptible E. faecalis OG1X, ampicil-
lin alone and all ampicillin-cephalosporin combinations demon-
strated bactericidal activity. Due to the considerable activity of
ampicillin alone, ampicillin-cephalosporin combinations were
not significantly more active. Ampicillin-gentamicin demon-
strated regrowth at 24 h.
We used a high-dose once-daily gentamicin regimen in this
study, similar to that recommended by recent European guide-
lines for enterococcal endocarditis (24). Previous studies have
found no difference in humans or rabbits with gentamicin inter-
vals of once, twice, or thrice daily (25, 26). Of importance, peni-
cillins can accelerate the degradation of aminoglycosides in vitro
(41). It remains possible, however, that activity against the gen-
tamicin-susceptible isolate could have been increased by using
gentamicin every 8 or 12 h. Additionally, an increase in other
antibiotics, such as ceftaroline every 8 h, might increase activity
against enterococci, particularly those with higher ceftaroline
MICs.
Against our high-level aminoglycoside-resistant (HLAR),
-lactamase-producing ampicillin-susceptible isolate (HH22),
ampicillin alone demonstrated bacteriostatic activity, but combi-
nations with cefepime or ceftaroline demonstrated bactericidal
activity at 24 h. These ampicillin-cefepime and ampicillin-ceftaro-
line combinations were more active than ampicillin alone (mean
difference in log10 CFU/ml, 2.49; 95% confidence interval [95%
CI], 0.46 to 4.52; P  0.01, and 3.62; 95% CI, 1.59 to 5.65; P 
0.001). Ampicillin-ceftriaxone did not significantly increase activ-
ity over that of ampicillin alone but was also not significantly
different from the other cephalosporin combinations. Against this
HLAR isolate, there was regrowth at 24 h with all monotherapy
regimens and ampicillin-gentamicin. Despite regrowth, no in-
creases in MIC were seen with any combination or ampicillin
monotherapy. There was no regrowth with ampicillin-cefepime
or ampicillin-ceftaroline.
Enterococcal-lactamase production has a negligible effect on
ampicillin MIC at standard testing inocula but raises the MIC
when tested at high inocula (27). The significant differences we
observed in the activities of ampicillin alone against the two
strains in this study are consistent with these prior studies of
HH22. Our results are encouraging in that the reduced efficacy of
ampicillin against the -lactamase-producing strain was over-
come by the addition of cefepime or ceftaroline. Our study is
limited by the use of two strains and the 24-h duration. Additional
research will be required before the efficacy of cefepime and cef-
taroline againstE. faecalis endocarditis in the clinical setting can be
determined.
Overall, ampicillin-cephalosporin combinations demonstrated
the greatest activity against both strains. Activity with dual--
lactam therapy may be isolate dependent and likely depends on
the isolate’s susceptibility to ampicillin alone. While the rate of
susceptibility to ampicillin remains at 95% in E. faecalis, up to
60% of bloodstream isolates in the United States in 2010 were
gentamicin resistant, necessitating other synergistic treatment op-
tions (28–30). The synergy of ampicillin-cephalosporin combina-
tions is thought to be due to complementary penicillin binding
protein (PBP) saturation (31). Cephalosporins bind to PBP 2 and
3 at low concentrations, providing total saturation. Ampicillin
binds to PBP 4 and 5, inhibiting cell wall synthesis (31). This same
mechanism has been shown with amoxicillin-cefotaxime and
amoxicillin-ceftriaxone (31, 32). The synergistic effect demon-
strated in our study between ampicillin-cefepime and ampicillin-
ceftaroline is predictable and increases the possibilities of addi-
tional treatment options for enterococcal endocarditis.
Previous studies have associated ceftriaxone usewith bothVRE
colonization and bacteremia (7, 8). The high biliary excretion of
ceftriaxone selects for the survival of VRE; this increased coloni-
zation does not occur with other cephalosporins that do not un-
dergo significant biliary excretion (6, 7, 9, 11). The high levels of
ceftriaxone in the gastrointestinal tract (up to 67% biliary excre-
tion) inhibit colonic microbiota, but due to their intrinsic resis-
tance to cephalosporins (along with ampicillin and vancomycin
resistance), VRE growth is left unchecked (7, 33). The complex
interactions between colonic flora, innate immunity, antimicro-
bial spectrum, and gastrointestinal antimicrobial concentration
likely all contribute to VRE colonization, but these relationships
have not been clearly determined (7, 33). Antienterococcal and
antianaerobic activities are important for VRE colonization, but
VRE expansion does not always correlate with the numbers of
anaerobes present (10, 34). Both gut anaerobes and Gram-nega-
tive bacteria interact withVRE growth and the immune regulation
of VRE (34, 35). In hospitalized patients, rates of VRE acquisition
can be as high as 41% (30). Bacteremia with HLAR enterococci,
which has demonstrated increased mortality over that with non-
HLAR bacteremia, was also associated with previous third-gener-
ation cephalosporin use, likely ceftriaxone (36).
TABLE 1 MICs by Etest against two strains of E. faecalis
Drug









Gentamicin 12 (S) 500 (R)
a S, susceptible per CLSI guidelines; R, resistant per CLSI guidelines. *, no CLSI
breakpoints for cephalosporins against enterococci.
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Cefepime carries less risk of promoting VRE colonization in
animals and has not been associated with VRE in humans (6, 10).
This may be due to the low biliary excretion (95% renal excre-
tion) and lack of antianaerobic activity (10, 19). The narrower
spectrumof activity of ceftaroline, coupledwith its renal excretion
and high activity in this study, make ampicillin-ceftaroline a
promising combination for E. faecalis endocarditis. Despite in-
trinsic resistance, ceftaroline monotherapy has demonstrated in
vitro and in vivo activity against E. faecalis (37). The ampicillin-
ceftaroline combination has previously demonstrated synergy
against E. faecalis in an in vitro time-kill study (38). Further study
of VRE colonization with ceftaroline is needed, as the antianaero-
bic activity is 4- to 8-fold greater than that of ceftriaxone, but
biliary excretion is lower (6% excreted in feces) (39, 40).
In our study, ampicillin-cephalosporin combinations demon-
strated the most activity against both strains of E. faecalis over 24
FIG 1 Activities (mean log10 CFU/ml standard deviation) of ampicillin (AMP), ceftriaxone (CRO), cefepime (FEP), ceftaroline (CTAR), gentamicin (GEN),
and growth control (GC) regimens against two E. faecalis isolates over 24 h in an in vitro pharmacodynamic model.
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h. Ampicillin-cefepime and ampicillin-ceftaroline significantly
increased activity over that of ampicillin alone for one strain. Du-
al--lactam regimens should be investigated further, not only for
activity, but also with regard to colonization and infection with
vancomycin-resistant enterococci.
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